[
  "INDICATIONS AND USAGE-------------------------- with CML are diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, BOSULIF is a kinase inhibitor indicated for the treatment of hepatic dysfunction, headache, pyrexia, decreased appetite respiratory tract \ninfection, and constipation. The most common laboratory abnormalities \u2022 adult and pediatric patients 1 year of age and older with chronic phase Ph+ (\u226520%) in adult and pediatric patients are creatinine increased, hemoglobin chronic myelogenous leukemia (CML), newly-diagnosed or resistant or decreased, lymphocyte count decreased, platelets decreased, ALT intolerant to prior therapy. (1) increased, calcium decreased, white blood cell count decreased, AST \n\u2022 adult patients with accelerated, or blast phase Ph+ CML with resistance or increased, absolute neutrophil count decreased, glucose increased, intolerance to prior therapy. (1) phosphorus decreased, urate increased, alkaline phosphatase increased, \nlipase increased, creatine kinase increased, and amylase increased. (6.1) ----------------------",
  "INDICATIONS AND USAGE---------------------------- \nSPRYCEL is a kinase inhibitor indicated for the treatment of  \n\u2022 newly diagnosed adults with Philadelphia chromosome-positive (Ph+) \nchronic myeloid leukemia (CML) in chronic phase. (1, 14) \n\u2022 adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ \nCML with resistance or intolerance to prior therapy including imatinib. (1, \n14) \n\u2022 adults with Philadelphia chromosome-positive acute lymphoblastic \nleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) \n\u2022 pediatric patients 1 year of age and older with Ph+ CML in chronic phase. \n(1, 14) \n\u2022 pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in \ncombination with chemotherapy. (1, 14) \n-----------------------",
  "INDICATIONS AND USAGE----------------------------\nGleevec is a kinase inhibitor indicated for the treatment of: \n\u2022\t Newly diagnosed adult and pediatric patients with Philadelphia \nchromosome positive chronic myeloid leukemia (Ph+ CML) in chronic \nphase (1.1) \n\u2022\t Patients with Philadelphia chromosome positive chronic myeloid leukemia \n(Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase \n(CP) after failure of interferon-alpha therapy (1.2) \n\u2022\t Adult patients with relapsed or refractory Philadelphia chromosome \npositive acute lymphoblastic leukemia (Ph+ ALL) (1.3) \n\u2022\t Pediatric patients with newly diagnosed Philadelphia chromosome positive \nacute lymphoblastic leukemia (Ph+ ALL) in combination with \nchemotherapy (1.4) \n\u2022\t Adult patients with myelodysplastic/myeloproliferative diseases \n(MDS/MPD) associated with PDGFR (platelet-derived growth factor \nreceptor) gene re-arrangements (1.5) \n\u2022\t Adult patients with aggressive systemic mastocytosis (ASM) without the \nD816V c-Kit mutation or with c-Kit mutational status unknown (1.6) \n\u2022\t Adult patients with hypereosinophilic syndrome (HES) and/or chronic \neosinophilic leukemia (CEL) who have the FIP1L1-PDGFR\u03b1 fusion kinase \n(mutational analysis or FISH demonstration of CHIC2 allele deletion) and \nfor patients with HES and/or CEL who are FIP1L1-PDGFR\u03b1 fusion kinase \nnegative or unknown (1.7) \n\u2022\t Adult patients with unresectable, recurrent and/or metastatic \ndermatofibrosarcoma protuberans (DFSP) (1.8) \n\u2022\t Patients with Kit (CD117) positive unresectable and/or metastatic \nmalignant gastrointestinal stromal tumors (GIST) (1.9) \n\u2022\t Adjuvant treatment of adult patients following resection of Kit (CD117) \npositive GIST (1.10) \n-----------------------",
  "INDICATIONS AND USAGE-------------------------\u00ad\nSCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients \nwith: \n\u2022\t Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) \nin chronic phase (CP), previously treated with two or more tyrosine kinase \ninhibitors (TKIs). (1) \nThis indication is approved under accelerated approval based on major \nmolecular response (MMR).  Continued approval for this indication may be \ncontingent upon verification and description of clinical benefit in a \nconfirmatory trial(s). \n\u2022\t Ph+ CML in CP with the T315I mutation. (1) \n----------------------",
  "INDICATIONS AND USAGE---------------------------\u00ad\nALECENSA is a kinase inhibitor indicated for the treatment of patients with \nanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung \ncancer (NSCLC) as detected by an FDA-approved test. (1) \n-----------------------",
  "INDICATIONS AND USAGE----------------------------\nXALKORI is a kinase inhibitor indicated for the treatment of \n\uf0b7 patients with metastatic non-small cell lung cancer (NSCLC) whose \ntumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as \ndetected by an FDA-approved test. (1.1, 2.1)\n\uf0b7 pediatric patients 1 year of age and older and young adults with relapsed \nor refractory, systemic anaplastic large cell lymphoma (ALCL) that is \nALK-positive. (1.2, 2.2) \no Limitations of Use: The safety and efficacy of XALKORI have not\nbeen established in older adults with relapsed or refractory, \nsystemic ALK-positive ALCL.\n\uf0b7 adult and pediatric patients 1 year of age and older with unresectable, \nrecurrent, or refractory inflammatory myofibroblastic tumor (IMT) that\nis ALK-positive. (1.3, 2.2)\n-----------------------",
  "INDICATIONS AND USAGE---------------------------- females of reproductive potential to use an effective non-hormonal \nLORBRENA is a kinase inhibitor indicated for the treatment of patients with method of contraception. (5.6, 7.2, 8.1, 8.3) \nanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung \ncancer (NSCLC) whose disease has progressed on ------------------------------ ADVERSE REACTIONS -----------------------------\u00ad\n\u2022 crizotinib and at least one other ALK inhibitor for metastatic disease; or\t Most common adverse reactions (incidence \u226520%) are edema, peripheral \n\u2022\t alectinib as the first ALK inhibitor therapy for metastatic disease; or neuropathy, cognitive effects, dyspnea, fatigue, weight gain, arthralgia, mood \neffects, and diarrhea. (6.1) \u2022\t ceritinib as the first ALK inhibitor therapy for metastatic disease. \nThis indication is approved under accelerated approval based on tumor To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at\nresponse rate and duration of response. Continued approval for this indication 1-800-438-1985 or www.pfizer.com or FDA at 1-800-FDA-1088 or\nmay be contingent upon verification and description of clinical benefit in a www.fda.gov/medwatch.\nconfirmatory trial. (1)\n------------------------------ DRUG INTERACTIONS------------------------------\u00ad\n-----------------------",
  "INDICATIONS AND USAGE--------------------------\nZYKADIA is a kinase inhibitor indicated for the treatment of adults with \nmetastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic \nlymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1, \n2.1) \n--------------------------",
  "INDICATIONS AND USAGE______________________ \nPEMAZYRE is a kinase inhibitor indicated: \nfor the treatment of adults with previously treated, unresectable locally \nadvanced or metastatic cholangiocarcinoma with a fibroblast growth factor \nreceptor 2 (FGFR2) fusion or other rearrangement as detected by an \nFDA-approved test. (1,2.1) \nThis indication is approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for this \nindication may be contingent upon verification and description of clinical \nbenefit in a confirmatory trial(s). (1,2.1) \nFor the treatment of adults with relapsed or refractory myeloid/lymphoid \nneoplasms (MLNs) with FGFR1 rearrangement. (1,2.1)",
  "INDICATIONS AND USAGE-------------------------\u00ad\nTRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with \npreviously treated, unresectable locally advanced or metastatic \ncholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) \nfusion or other rearrangement as detected by an FDA-approved test. (1, 2.1) \nThis indication is approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for this indication \nmay be contingent upon verification and description of clinical benefit in \nconfirmatory trial(s). (1) \n------------------------",
  "INDICATIONS AND USAGE---------------------------\nBALVERSA is a kinase inhibitor indicated for the treatment of adult patients \nwith locally advanced or metastatic urothelial carcinoma (mUC) with \nsusceptible FGFR3 genetic alterations whose disease has progressed on or \nafter at least one line of prior systemic therapy. \nSelect patients for therapy based on an FDA-approved companion diagnostic \nfor BALVERSA. (1, 2.1) \nLimitations of Use \nBALVERSA is not recommended for the treatment of patients who are \neligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (1, \n14.1) \n------------------------",
  "INDICATIONS AND USAGE--------------------------- \nVITRAKVI is a kinase inhibitor indicated for the treatment of adult and \npediatric patients with solid tumors that: \n\u2022 have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a \nknown acquired resistance mutation,  \n\u2022 are metastatic or where surgical resection is likely to result in severe \nmorbidity, and  \n\u2022 have no satisfactory alternative treatments or that have progressed \nfollowing treatment. \nThis indication is approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for this indication \nmay be contingent upon verification and description of clinical benefit in \nconfirmatory trials (1,14). \n----------------------",
  "INDICATIONS AND USAGE----------------------------\nROZLYTREK is a kinase inhibitor indicated for the treatment of: \n\u2022 Adult patients with ROS1-positive metastatic non-small cell lung cancer \n(NSCLC) as detected by an FDA-approved test. (1.1) \n\u2022 Adult and pediatric patients older than 1 month of age with solid tumors \nthat: \no have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as \ndetected by an FDA-approved test without a known acquired resistance \nmutation, \no are metastatic or where surgical resection is likely to result in severe \nmorbidity, and \no have progressed following treatment or have no satisfactory alternative \ntherapy. \nThis indication is approved under accelerated approval based on tumor \nresponse rate and durability of response. Continued approval for this \nindication may be contingent upon verification and description of clinical \nbenefit in the confirmatory trials. (1.2) \n-----------------------",
  "INDICATIONS AND USAGE ---------------------------\nRETEVMO\u00ae is a kinase inhibitor indicated for the treatment of: \n\u2022 Adult patients with locally advanced or metastatic non-small cell lung \ncancer (NSCLC) with a rearranged during transfection (RET) gene \nfusion, as detected by an FDA-approved test (1.1) \n\u2022 Adult and pediatric patients 12 years of age and older with advanced \nor metastatic medullary thyroid cancer (MTC) with a RET mutation, as \ndetected by an FDA-approved test, who require systemic therapy1 \n(1.2) \n\u2022 Adult and pediatric patients 12 years of age and older with advanced \nor metastatic thyroid cancer with a RET gene fusion, as detected by an \nFDA-approved test, who require systemic therapy and who are \nradioactive iodine-refractory (if radioactive iodine is appropriate)1 (1.3) \n\u2022 Adult patients with locally advanced or metastatic solid tumors with a \nRET gene fusion that have progressed on or following prior systemic \ntreatment or who have no satisfactory alternative treatment options1 \n(1.4) \nThis indication is approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for this \nindication may be contingent upon verification and description of clinical \nbenefit in confirmatory trial(s). \n------------------------",
  "INDICATIONS AND USAGE \nGAVRETO is a kinase inhibitor indicated for treatment of: \n\u2022 Adult patients with metastatic rearranged during transfection (RET) \nfusion-positive non-small cell lung cancer as detected by an FDA \napproved test (NSCLC). (1.1) \n\u2022 Adult and pediatric patients 12 years of age and older with advanced or \nmetastatic RET fusion-positive thyroid cancer who require systemic \ntherapy and who are radioactive iodine-refractory (if radioactive iodine \nis appropriate). \nThis indication is approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for this \nindication may be contingent upon verification and description of \nclinical benefit in confirmatory trial(s). (1.2) \n_______________",
  "INDICATIONS AND USAGE  --------------------------  \nLynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: \nOvarian cancer \n\u2022 for the maintenance treatment of adult patients with deleterious or \nsuspected deleterious germline or somatic BRCA-mutated advanced \nepithelial ovarian, fallopian tube or primary peritoneal cancer who are in \ncomplete or partial response to first-line platinum-based chemotherapy. \nSelect patients for therapy based on an FDA-approved companion \ndiagnostic for Lynparza. (1.1, 2.1) \n\u2022 in combination with bevacizumab for the maintenance treatment of adult \npatients with advanced epithelial ovarian, fallopian tube or primary \nperitoneal cancer who are in complete or partial response to first-line \nplatinum-based chemotherapy and whose cancer is associated with \nhomologous recombination deficiency (HRD)-positive status defined by \neither: \n\u2022 a deleterious or suspected deleterious BRCA mutation, and/or  \n\u2022 genomic instability.  \nSelect patients for therapy based on an FDA-approved companion \ndiagnostic for Lynparza (1.2, 2.1). \n\u2022 for the maintenance treatment of adult patients with recurrent epithelial \novarian, fallopian tube or primary peritoneal cancer, who are in \ncomplete or partial response to platinum-based chemotherapy. (1.3) \nBreast cancer \n\u2022 for the adjuvant treatment of adult patients with deleterious or suspected \ndeleterious gBRCAm human epidermal growth factor receptor 2 \n(HER2)-negative high risk early breast cancer who have been treated \nwith neoadjuvant or adjuvant chemotherapy. Select patients for therapy \nbased on an FDA-approved companion diagnostic for Lynparza. (1.4, \n2.1). \n\u2022 for the treatment of adult patients with deleterious or suspected \ndeleterious gBRCAm, HER2-negative metastatic breast cancer who have \nbeen treated with chemotherapy in the neoadjuvant, adjuvant or \nmetastatic setting. Patients with hormone receptor (HR)-positive breast \ncancer should have been treated with a prior endocrine therapy or be \nconsidered inappropriate for endocrine therapy. Select patients for \ntherapy based on an FDA-approved companion diagnostic for Lynparza. \n(1.5, 2.1) \nPancreatic cancer \n\u2022 for the maintenance treatment of adult patients with deleterious or \nsuspected deleterious gBRCAm metastatic pancreatic adenocarcinoma \nwhose disease has not progressed on at least 16 weeks of a first-line \nplatinum-based chemotherapy regimen. Select patients for therapy based \non an FDA-approved companion diagnostic for Lynparza. (1.6, 2.1) \nProstate cancer \n\u2022 for the treatment of adult patients with deleterious or suspected \ndeleterious germline or somatic homologous recombination repair \n(HRR) gene-mutated metastatic castration-resistant prostate cancer \n(mCRPC) who have progressed following prior treatment with \nenzalutamide or abiraterone. Select patients for therapy based on an \nFDA-approved companion diagnostic for Lynparza. (1.7, 2.1) \n\u2022 in combination with abiraterone and prednisone or prednisolone for the \ntreatment of adult patients with deleterious or suspected deleterious \nBRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer \n(mCRPC). Select patients for therapy based on an FDA-approved \ncompanion diagnostic for Lynparza. (1.8, 2.1) \n ----------------------",
  "INDICATIONS AND USAGE----------------------------\nTAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of \npatients with unresectable or metastatic melanoma with BRAF V600E \nmutation as detected by an FDA-approved test. (1.1, 2.1) \nTAFINLAR is indicated, in combination with trametinib, for: \n\u2022 the treatment of patients with unresectable or metastatic melanoma with \nBRAF V600E or V600K mutations as detected by an FDA-approved test. \n(1.2, 2.1) \n\u2022 the adjuvant treatment of patients with melanoma with BRAF V600E or \nV600K mutations, as detected by an FDA-approved test, and involvement \nof lymph node(s), following complete resection. (1.3, 2.1) \n\u2022 the treatment of patients with metastatic non-small cell lung cancer \n(NSCLC) with BRAF V600E mutation as detected by an FDA-approved \ntest. (1.4, 2.1) \n\u2022 the treatment of patients with locally advanced or metastatic anaplastic \nthyroid cancer (ATC) with BRAF V600E mutation and with no \nsatisfactory locoregional treatment options. (1.5, 2.1) \n\u2022 the treatment of adult and pediatric patients 6 years of age and older with \nunresectable or metastatic solid tumors with BRAF V600E mutation who \nhave progressed following prior treatment and have no satisfactory \nalternative treatment options. This indication is approved under \naccelerated approval based on overall response rate and duration of \nresponse. Continued approval for this indication may be contingent upon \nverification and description of clinical benefit in a confirmatory trial(s). \n(1.6, 2.1) \n\u2022 the treatment of pediatric patients 1 year of age and older with low-grade \nglioma (LGG) with a BRAF V600E mutation who require systemic \ntherapy. (1.7, 2.1) \nLimitations of Use: TAFINLAR is not indicated for treatment of patients with \ncolorectal cancer because of known intrinsic resistance to BRAF inhibition \n(1.8, 12.1). TAFINLAR is not indicated for treatment of patients with wild-\ntype BRAF solid tumors. (5.2) \n-----------------------",
  "INDICATIONS AND USAGE-------------------------\nMEKINIST is a kinase inhibitor indicated as a single agent for the treatment \nof BRAF-inhibitor treatment-na\u00efve patients with unresectable or metastatic \nmelanoma with BRAF V600E or V600K mutations as detected by an FDA-\napproved test. (1.1, 2.1) \nMEKINIST is indicated, in combination with dabrafenib, for: \n\uf0b7\t the treatment of patients with unresectable or metastatic melanoma with \nBRAF V600E or V600K mutations as detected by an FDA-approved \ntest. (1.1, 2.1) \n\uf0b7\t the adjuvant treatment of patients with melanoma with BRAF V600E or \nV600K mutations, as detected by an FDA-approved test, and \ninvolvement of lymph node(s), following complete resection. (1.2, 2.1) \n\uf0b7\t the treatment of patients with metastatic non-small cell lung cancer \n(NSCLC) with BRAF V600E mutation as detected by an FDA-approved \ntest. (1.3, 2.1) \n\uf0b7\t the treatment of patients with locally advanced or metastatic anaplastic \nthyroid cancer (ATC) with BRAF V600E mutation and with no \nsatisfactory locoregional treatment options. (1.4, 2.1) \n-------------------------",
  "INDICATIONS AND USAGE-------------------------\nBRAFTOVI is a kinase inhibitor indicated: \n\uf0b7 in combination with binimetinib, for the treatment of patients with \nunresectable or metastatic melanoma with a BRAF V600E or V600K \nmutation, as detected by an FDA-approved test. (1.1, 2.1)\n\uf0b7 in combination with cetuximab, for the treatment of adult patients \nwith metastatic colorectal cancer (CRC) with a BRAF V600E \nmutation, as detected by an FDA-approved test, after prior therapy. \n(1.2, 2.1)\n\uf0b7 in combination with binimetinib, for the treatment of adult patients \nwith metastatic non-small cell lung cancer (NSCLC) with a BRAF \nV600E mutation, as detected by an FDA-approved test. (1.3, 2.1)\nLimitations of Use\nBRAFTOVI is not indicated for treatment of patients with wild-type BRAF \nmelanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. (1.4, 5.2)\n---------------------",
  "INDICATIONS AND USAGE---------------------------\u00ad\n\u2022\t ZELBORAF\u00ae is a kinase inhibitor indicated for the treatment of patients \nwith unresectable or metastatic melanoma with BRAF V600E mutation as \ndetected by an FDA-approved test. (1.1, 2.1) \n\u2022\t ZELBORAF\u00ae is indicated for the treatment of patients with Erdheim-\nChester Disease with BRAF V600 mutation. (1.2, 2.1) \nLimitation of Use: ZELBORAF is not indicated for treatment of patients with \nwild-type BRAF melanoma (2.1, 5.2) \n-----------------------",
  "INDICATIONS AND USAGE---------------------------\u00ad\nRUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: \nOvarian cancer \n\u2022\t for the maintenance treatment of adult patients with recurrent epithelial \novarian, fallopian tube, or primary peritoneal cancer who are in a complete \nor partial response to platinum-based chemotherapy. (1.1) \n\u2022\t for the treatment of adult patients with a deleterious BRCA mutation \n(germline and/or somatic)-associated epithelial ovarian, fallopian tube, or \nprimary peritoneal cancer who have been treated with two or more \nchemotherapies. Select patients for therapy based on an FDA-approved \ncompanion diagnostic for RUBRACA. (1.1, 2.1) \nProstate cancer \n\u2022\t for the treatment of adult patients with a deleterious BRCA mutation \n(germline and/or somatic)-associated metastatic castration-resistant prostate \ncancer (mCRPC) who have been treated with androgen receptor-directed \ntherapy and a taxane-based chemotherapy. Select patients for therapy based \non an FDA-approved companion diagnostic for RUBRACA. (1.2, 2.1) \nThis indication is approved under accelerated approval based on objective \nresponse rate and duration of response. Continued approval for this \nindication may be contingent upon verification and description of clinical \nbenefit in confirmatory trials. (1.2) \n-----------------------",
  "INDICATIONS AND USAGE \nZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated: \n\uf0b7 for the maintenance treatment of adult patients with advanced \nepithelial ovarian, fallopian tube, or primary peritoneal cancer who \nare in a complete or partial response to first-line platinum-based \nchemotherapy. (1.1) \n\uf0b7 for the maintenance treatment of adult patients with recurrent \nepithelial ovarian, fallopian tube, or primary peritoneal cancer who \nare in a complete or partial response to platinum-based \nchemotherapy. (1.2) \n\uf0b7 for the treatment of adult patients with advanced ovarian, fallopian \ntube, or primary peritoneal cancer who have been treated with three \nor more prior chemotherapy regimens and whose cancer is \nassociated with homologous recombination deficiency (HRD) \npositive status defined by either: \n\uf0b7\t a deleterious or suspected deleterious BRCA mutation, or \n\uf0b7\t genomic instability and who have progressed more than six \nmonths after response to the last platinum-based \nchemotherapy. \nSelect patients for therapy based on an FDA-approved companion \ndiagnostic for ZEJULA. (1.3, 2.1)",
  "INDICATIONS AND USAGE --------------------------\nTAGRISSO is a kinase inhibitor indicated for: \n\uf0b7 adjuvant therapy after tumor resection in adult patients with non-small \ncell lung cancer (NSCLC) whose tumors have epidermal growth factor \nreceptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as \ndetected by an FDA-approved test (1.1, 2.2) \n\uf0b7 the first-line treatment of adult patients with metastatic NSCLC whose \ntumors have EGFR exon 19 deletions or exon 21 L858R mutations, as \ndetected by an FDA-approved test. (1.2, 2.2) \n\uf0b7 in combination with pemetrexed and platinum-based chemotherapy, the \nfirst-line treatment of adult patients with locally advanced or metastatic \nNSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R \nmutations, as detected by an FDA-approved test. (1.3, 2.2) \n\uf0b7 the treatment of adult patients with metastatic EGFR T790M mutation-\npositive NSCLC, as detected by an FDA-approved test, whose disease has \nprogressed on or after EGFR TKI therapy. (1.4, 2.2) \n----------------------",
  "INDICATIONS AND USAGE--------------------------\u00ad\nGILOTRIF is a kinase inhibitor indicated for: \n\u2022\t First-line treatment of patients with metastatic non-small cell lung cancer \n(NSCLC) whose tumors have non-resistant epidermal growth factor \nreceptor (EGFR) mutations as detected by an FDA-approved test (1.1) \nLimitations of Use: Safety and efficacy of GILOTRIF were not established \nin patients whose tumors have resistant EGFR mutations (1.1) \n\u2022\t Treatment of patients with metastatic, squamous NSCLC progressing after \nplatinum-based chemotherapy (1.2) \n----------------------",
  "INDICATIONS AND USAGE---------------------------\nRYBREVANT is a bispecific EGF receptor-directed and MET receptor-\ndirected antibody indicated: \n\u2022 in combination with carboplatin and pemetrexed for the first-line treatment \nof adult patients with locally advanced or metastatic non-small cell lung cancer \n(NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion \nmutations, as detected by an FDA-approved test. (1, 2.2) \n\u2022 as a single agent for the treatment of adult patients with locally advanced or \nmetastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an \nFDA-approved test, whose disease has progressed on or after platinum-based \nchemotherapy. (1, 2.2) \n------------------------",
  "INDICATIONS AND USAGE--------------------------\u00ad\nEXKIVITY is a kinase inhibitor indicated for the treatment of adult \npatients with locally advanced or metastatic non-small cell lung cancer \n(NSCLC) with epidermal growth factor receptor (EGFR) exon 20 \ninsertion mutations, as detected by an FDA-approved test, whose \ndisease has progressed on or after platinum-based chemotherapy. \nThis indication is approved under accelerated approval based on \noverall response rate and duration of response. Continued approval for \nthis indication may be contingent upon verification and description of \nclinical benefit in confirmatory trial(s). (1, 2.1) \n------------------------",
  "INDICATIONS AND USAGE -------------------------\u00ad\nTAZVERIK is a methyltransferase inhibitor indicated for the treatment of: \n\u2022\t Adults and pediatric patients aged 16 years and older with metastatic or \nlocally advanced epithelioid sarcoma not eligible for complete resection. \n(1.1) \n\u2022\t Adult patients with relapsed or refractory follicular lymphoma whose \ntumors are positive for an EZH2 mutation as detected by an \nFDA-approved test and who have received at least 2 prior systemic \ntherapies. (1.2) \n\u2022\t Adult patients with relapsed or refractory follicular lymphoma who have \nno satisfactory alternative treatment options. (1.2) \nThese indications are approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for these \nindications may be contingent upon verification and description of clinical \nbenefit in a confirmatory trial(s). \n-----------------------",
  "INDICATIONS AND USAGE------------------------------ \nTIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for \npatients with a susceptible IDH1 mutation as detected by an FDA-approved test \nwith: \nNewly Diagnosed Acute Myeloid Leukemia (AML) \n\u2022 In combination with azacitidine or as monotherapy for the treatment of newly \ndiagnosed AML in adults 75 years or older, or who have comorbidities that \npreclude use of intensive induction chemotherapy (1.1).   \nRelapsed or refractory AML  \n\u2022 For the treatment of adult patients with relapsed or refractory AML (1.2). \nRelapsed or refractory Myelodysplastic Syndromes (MDS)  \n\u2022 For the treatment of adult patients with relapsed or refractory \nmyelodysplastic syndromes (1.3). \nLocally Advanced or Metastatic Cholangiocarcinoma \n\u2022 For the treatment of adult patients with locally advanced or metastatic \ncholangiocarcinoma who have been previously treated (1.4). \n-----------------------",
  "INDICATIONS AND USAGE----------------------------\nIDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment \nof adult patients with relapsed or refractory acute myeloid leukemia (AML) \nwith an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-\napproved test (1.1). \n-----------------------",
  "INDICATIONS AND USAGE -------------------------\u00ad\nSTIVARGA is a kinase inhibitor indicated for the treatment of patients with: \n\u2022 Metastatic colorectal cancer (CRC) who have been previously treated with \nfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-\nVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. (1.1) \n\u2022 Locally advanced, unresectable or metastatic gastrointestinal stromal tumor \n(GIST) who have been previously treated with imatinib mesylate and \nsunitinib malate. (1.2) \n\u2022 Hepatocellular carcinoma (HCC) who have been previously treated with \nsorafenib (1.3) \n----------------------",
  "INDICATIONS AND USAGE---------------------------\u00ad\nSUTENT is a kinase inhibitor indicated for: \n\u2022\t treatment of adult patients with gastrointestinal stromal tumor (GIST) \nafter disease progression on or intolerance to imatinib mesylate. (1.1) \n\u2022\t treatment of adult patients with advanced renal cell carcinoma (RCC). \n(1.2) \n\u2022\t adjuvant treatment of adult patients at high risk of recurrent RCC \nfollowing nephrectomy. (1.3) \n\u2022\t treatment of progressive, well-differentiated pancreatic neuroendocrine \ntumors (pNET) in adult patients with unresectable locally advanced or \nmetastatic disease. (1.4) \n-----------------------",
  "INDICATIONS AND USAGE--------------------------\u00ad\nLUMAKRAS is an inhibitor of the RAS GTPase family indicated for the \ntreatment of adult patients with KRAS G12C-mutated locally advanced or \nmetastatic non-small cell lung cancer (NSCLC), as determined by an \nFDA-approved test, who have received at least one prior systemic therapy. (1) \nThis indication is approved under accelerated approval based on overall \nresponse rate (ORR) and duration of response (DOR). Continued approval for \nthis indication may be contingent upon verification and description of clinical \nbenefit in a confirmatory trial(s). (1) \n----------------------",
  "INDICATIONS AND USAGE \nTABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose \ntumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-\napproved test.   \n2",
  "INDICATIONS AND USAGE--------------------------\u00ad\nAYVAKIT is a kinase inhibitor indicated for: \nGastrointestinal Stromal Tumor (GIST) \n\u2022\t the treatment of adults with unresectable or metastatic GIST \nharboring a platelet-derived growth factor receptor alpha \n(PDGFRA) exon 18 mutation, including PDGFRA D842V \nmutations. (1.1, 2.1) \nAdvanced Systemic Mastocytosis (AdvSM) \n\u2022\t the treatment of adult patients with AdvSM. AdvSM includes \npatients with aggressive systemic mastocytosis (ASM), systemic \nmastocytosis with an associated hematological neoplasm (SM\u00ad\nAHN), and mast cell leukemia (MCL). (1.2) \n\u2022\t Limitations of Use: AYVAKIT is not recommended for the \ntreatment of patients with AdvSM with platelet counts of less than \n50 X 109/L (1.2) \n-----------------------",
  "INDICATIONS AND USAGE-------------------------\u00ad\nPIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the \ntreatment of postmenopausal women, and men, with hormone receptor (HR)\u00ad\npositive, human epidermal growth factor receptor 2 (HER2)-negative, \nPIK3CA-mutated, advanced or metastatic breast cancer as detected by an \nFDA-approved test following progression on or after an endocrine-based \nregimen. (1) \n----------------------",
  "INDICATIONS AND USAGE---------------------------\nAFINITOR is a kinase inhibitor indicated for the treatment of: \n\uf0b7\t Postmenopausal women with advanced hormone receptor-positive, HER2-\nnegative breast cancer in combination with exemestane after failure of \ntreatment with letrozole or anastrozole. (1.1) \n\uf0b7\t Adults with progressive neuroendocrine tumors of pancreatic origin \n(PNET) and adults with progressive, well-differentiated, non-functional \nneuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that \nare unresectable, locally advanced or metastatic. \nLimitations of Use: AFINITOR is not indicated for the treatment of \npatients with functional carcinoid tumors. (1.2) \n\uf0b7 Adults with advanced renal cell carcinoma (RCC) after failure of treatment \nwith sunitinib or sorafenib. (1.3) \n\uf0b7 Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), \nnot requiring immediate surgery. (1.4) \nAFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the \ntreatment of adult and pediatric patients aged 1 year and older with TSC who \nhave subependymal giant cell astrocytoma (SEGA) that requires therapeutic \nintervention but cannot be curatively resected. (1.5) \nAFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive \ntreatment of adult and pediatric patients aged 2 years and older with TSC-\nassociated partial-onset seizures. (1.6) \n------------------------",
  "INDICATIONS AND USAGE----------------------------\nTALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated \nfor: \nBreast Cancer \n\u2022 As a single agent, for the treatment of adult patients with deleterious or \nsuspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative \nlocally advanced or metastatic breast cancer. Select patients for therapy \nbased on an FDA-approved companion diagnostic for TALZENNA. (1.1) \nHRR Gene-mutated mCRPC \n\u2022 In combination with enzalutamide for the treatment of adult patients with \nHRR gene-mutated metastatic castration-resistant prostate cancer \n(mCRPC). (1.2) \n----------------------",
  "INDICATIONS AND USAGE\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7 \nKADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate \nindicated, as a single agent, for: \n\u2022\t the treatment of patients with HER2-positive, metastatic breast cancer \nwho previously received trastuzumab and a taxane, separately or in \ncombination. Patients should have either: \n\u2022\t received prior therapy for metastatic disease, or \n\u2022\t developed disease recurrence during or within six months of \ncompleting adjuvant therapy. (1.1) \n\u2022\t the adjuvant treatment of patients with HER2-positive early breast cancer \nwho have residual invasive disease after neoadjuvant taxane and \ntrastuzumab-based treatment. (1.2) \nSelect patients for therapy based on an FDA-approved companion diagnostic \nfor KADCYLA [see Dosage and Administration (2.1)] \n\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7",
  "INDICATIONS AND USAGE------------------------------ \nTYKERB is a kinase inhibitor indicated in combination with: (1) \n\uf0b7 capecitabine for the treatment of patients with advanced or metastatic breast \ncancer whose tumors overexpress human epidermal growth factor receptor 2 \n(HER2) and who have received prior therapy including an anthracycline, a \ntaxane, and trastuzumab. \nLimitations of Use: Patients should have disease progression on trastuzumab \nprior to initiation of treatment with TYKERB in combination with capecitabine. \n\uf0b7 letrozole for the treatment of postmenopausal women with hormone receptor-\npositive metastatic breast cancer that overexpresses the HER2 receptor for \nwhom hormonal therapy is indicated. \nTYKERB in combination with an aromatase inhibitor has not been compared to a \ntrastuzumab-containing chemotherapy regimen for the treatment of metastatic \nbreast cancer. \n----------------------------",
  "INDICATIONS AND USAGE \nNERLYNX is a kinase inhibitor indicated: \n\u2022\t As a single agent, for the extended adjuvant treatment of adult patients with \nearly-stage HER2-positive breast cancer, to follow adjuvant trastuzumab\u00ad\nbased therapy. (1.1) \n\u2022\t In combination with capecitabine, for the treatment of adult patients with \nadvanced or metastatic HER2-positive breast cancer who have received \ntwo or more prior anti-HER2 based regimens in the metastatic setting. (1.2) \n_______________",
  "INDICATIONS AND USAGE---------------------------\u00ad\nPERJETA is a HER2/neu receptor antagonist indicated for: \n\u2022\t Use in combination with trastuzumab and docetaxel for treatment of \npatients with HER2-positive metastatic breast cancer (MBC) who have \nnot received prior anti-HER2 therapy or chemotherapy for metastatic \ndisease. (1.1) \n\u2022\t Use in combination with trastuzumab and chemotherapy as \no\t neoadjuvant treatment of patients with HER2-positive, locally \nadvanced, inflammatory, or early stage breast cancer (either greater \nthan 2 cm in diameter or node positive) as part of a complete \ntreatment regimen for early breast cancer. (1.2, 2.2, 14.2) \no\t adjuvant treatment of patients with HER2-positive early breast cancer \nat high risk of recurrence (1.2, 2.2, 14.3) \n-----------------------",
  "INDICATIONS AND USAGE----------------------------\nHerceptin is a HER2/neu receptor antagonist indicated for: \n\u2022\t The treatment of HER2-overexpressing breast cancer. (1.1, 1.2) \n\u2022\t The treatment of HER2-overexpressing metastatic gastric or \ngastroesophageal junction adenocarcinoma. (1.3) \nSelect patients for therapy based on an FDA-approved companion diagnostic \nfor Herceptin (1, 2.1). \n------------------------",
  "INDICATIONS AND USAGE -----------------------------\nTUKYSA is a kinase inhibitor indicated: \n\u2022 in combination with trastuzumab and capecitabine for treatment of adult \npatients with advanced unresectable or metastatic HER2-positive breast \ncancer, including patients with brain metastases, who have received one \nor more prior anti-HER2-based regimens in the metastatic setting. (1.1) \n\u2022 in combination with trastuzumab for the treatment of adult patients with \nRAS wild-type HER2-positive unresectable or metastatic colorectal \ncancer that has progressed following treatment with fluoropyrimidine-, \noxaliplatin-, and irinotecan-based chemotherapy. (1.2) \nThis indication is approved under accelerated approval based on tumor \nresponse rate and durability of response [see Clinical Studies (14.2)]. \nContinued approval for this indication may be contingent upon \nverification and description of clinical benefit in confirmatory trials. \n----------------------",
  "INDICATIONS AND USAGE\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7 \nPHESGO is a combination of pertuzumab and trastuzumab, HER2/neu \nreceptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: \n\u2022\t Use in combination with chemotherapy as: \no\t neoadjuvant treatment of patients with HER2-positive, locally \nadvanced, inflammatory, or early stage breast cancer (either greater \nthan 2 cm in diameter or node positive) as part of a complete \ntreatment regimen for early breast cancer. (1.1) \no\t adjuvant treatment of patients with HER2-positive early breast \ncancer at high risk of recurrence (1.1) \n\u2022\t Use in combination with docetaxel for treatment of patients with HER2\u00ad\npositive metastatic breast cancer (MBC) who have not received prior \nanti-HER2 therapy or chemotherapy for metastatic disease. (1.2) \n\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7\uf8e7",
  "INDICATIONS AND USAGE---------------------------\u00ad\nMARGENZA is a HER2/neu receptor antagonist indicated, in combination \nwith chemotherapy, for the treatment of adult patients with metastatic HER2\u00ad\npositive breast cancer who have received two or more prior anti-HER2 \nregimens, at least one of which was for metastatic disease. (1, 2.1, 14.1) \n------------------------",
  "INDICATIONS AND USAGE----------------------------\nKEYTRUDA is a programmed death receptor-1 (PD-1)-blocking \nantibody indicated: \nMelanoma \n\u2022 for the treatment of patients with unresectable or metastatic \nmelanoma. (1.1) \n\u2022 for the adjuvant treatment of adult and pediatric (12 years and \nolder) patients with Stage IIB, IIC, or III melanoma following \ncomplete resection. (1.1) \nNon-Small Cell Lung Cancer (NSCLC) \n\u2022 in combination with pemetrexed and platinum chemotherapy, \nas first-line treatment of patients with metastatic nonsquamous \nNSCLC, with no EGFR or ALK genomic tumor aberrations. \n(1.2) \n\u2022 in combination with carboplatin and either paclitaxel or \npaclitaxel protein-bound, as first-line treatment of patients with \nmetastatic squamous NSCLC. (1.2) \n\u2022 as a single agent for the first-line treatment of patients with \nNSCLC expressing PD-L1 [Tumor Proportion Score (TPS) \n\u22651%] as determined by an FDA-approved test, with no EGFR \nor ALK genomic tumor aberrations, and is: \no Stage III where patients are not candidates for surgical \nresection or definitive chemoradiation, or \no metastatic. (1.2, 2.1) \n\u2022 as a single agent for the treatment of patients with metastatic \nNSCLC whose tumors express PD-L1 (TPS \u22651%) as \ndetermined by an FDA-approved test, with disease \nprogression on or after platinum-containing chemotherapy. \nPatients with EGFR or ALK genomic tumor aberrations should \nhave disease progression on FDA-approved therapy for these \naberrations prior to receiving KEYTRUDA. (1.2, 2.1) \n\u2022 for the treatment of patients with resectable (tumors \u22654 cm or \nnode positive) NSCLC in combination with platinum-containing \nchemotherapy as neoadjuvant treatment, and then continued \nas a single agent as adjuvant treatment after surgery. (1.2) \n\u2022 as a single agent, for adjuvant treatment following resection \nand platinum-based chemotherapy for adult patients with \nStage IB (T2a \u22654 cm), II, or IIIA NSCLC. (1.2) \nHead and Neck Squamous Cell Cancer (HNSCC) \n\u2022 in combination with platinum and FU for the first-line treatment \nof patients with metastatic or with unresectable, recurrent \nHNSCC. (1.3) \n\u2022 as a single agent for the first-line treatment of patients with \nmetastatic or with unresectable, recurrent HNSCC whose \ntumors express PD-L1 [Combined Positive Score (CPS) \u22651] as \ndetermined by an FDA-approved test. (1.3, 2.1) \n\u2022 as a single agent for the treatment of patients with recurrent or \nmetastatic HNSCC with disease progression on or after \nplatinum-containing chemotherapy. (1.3) \nClassical Hodgkin Lymphoma (cHL) \n\u2022 for the treatment of adult patients with relapsed or refractory \ncHL. (1.4) \n\u2022 for the treatment of pediatric patients with refractory cHL, or \ncHL that has relapsed after 2 or more lines of therapy. (1.4) \nPrimary Mediastinal Large B-Cell Lymphoma (PMBCL) \n\u2022 for the treatment of adult and pediatric patients with refractory \nPMBCL, or who have relapsed after 2 or more prior lines of \ntherapy. (1.5) \n\u2022 Limitations of Use: KEYTRUDA is not recommended for \ntreatment of patients with PMBCL who require urgent \ncytoreductive therapy. \nUrothelial Carcinoma \n\u2022 in combination with enfortumab vedotin, for the treatment of \nadult patients with locally advanced or metastatic urothelial \ncarcinoma who are not eligible for cisplatin-containing \nchemotherapy.1 (1.6) \n\u2022 as a single agent for the treatment of patients with locally \nadvanced or metastatic urothelial carcinoma who: \no are not eligible for any platinum-containing \nchemotherapy, or \no who have disease progression during or following \nplatinum-containing chemotherapy or within 12 months of \nneoadjuvant or adjuvant treatment with platinum-\ncontaining chemotherapy. (1.6) \n\u2022 as a single agent for the treatment of patients with Bacillus \nCalmette-Guerin (BCG)-unresponsive, high-risk, non-muscle \ninvasive bladder cancer (NMIBC) with carcinoma in situ (CIS) \nwith or without papillary tumors who are ineligible for or have \nelected not to undergo cystectomy. (1.6) \nMicrosatellite Instability-High or Mismatch Repair Deficient Cancer \n\u2022 for the treatment of adult and pediatric patients with \nunresectable or metastatic microsatellite instability-high \n(MSI-H) or mismatch repair deficient (dMMR) solid tumors, as \ndetermined by an FDA-approved test, that have progressed \nfollowing prior treatment and who have no satisfactory \nalternative treatment options. (1.7, 2.1) \nMicrosatellite Instability-High or Mismatch Repair Deficient \nColorectal Cancer (CRC) \n\u2022 for the treatment of patients with unresectable or metastatic \nMSI-H or dMMR colorectal cancer (CRC) as determined by an \nFDA-approved test. (1.8, 2.1) \nGastric Cancer \n\u2022 in combination with trastuzumab, fluoropyrimidine- and \nplatinum-containing chemotherapy, for the first-line treatment \nof patients with locally advanced unresectable or metastatic \nHER2-positive gastric or gastroesophageal junction (GEJ) \nadenocarcinoma whose tumors express PD-L1 (CPS \u22651) as \ndetermined by an FDA-approved test.1 (1.9) \nEsophageal Cancer \n\u2022 for the treatment of patients with locally advanced or metastatic \nesophageal or gastroesophageal junction (GEJ) (tumors with \nepicenter 1 to 5 centimeters above the GEJ) carcinoma that is \nnot amenable to surgical resection or definitive chemoradiation \neither: \no in combination with platinum- and fluoropyrimidine-based \nchemotherapy, or \no as a single agent after one or more prior lines of systemic \ntherapy for patients with tumors of squamous cell \nhistology that express PD-L1 (CPS \u226510) as determined \nby an FDA-approved test. (1.10, 2.1) \nCervical Cancer \n\u2022 in combination with chemotherapy, with or without \nbevacizumab, for the treatment of patients with persistent, \nrecurrent, or metastatic cervical cancer whose tumors express \nPD-L1 (CPS \u22651) as determined by an FDA-approved test. \n(1.11, 2.1) \n\u2022 as a single agent for the treatment of patients with recurrent or \nmetastatic cervical cancer with disease progression on or after \nchemotherapy whose tumors express PD-L1 (CPS \u22651) as \ndetermined by an FDA-approved test. (1.11, 2.1) \nHepatocellular Carcinoma (HCC) \n\u2022 for the treatment of patients with HCC who have been \npreviously treated with sorafenib.1 (1.12) \nBiliary Tract Cancer (BTC) \n\u2022 in combination with gemcitabine and cisplatin, for the \ntreatment of patients with locally advanced unresectable or \nmetastatic biliary tract cancer. (1.13) \nMerkel Cell Carcinoma (MCC) \n\u2022 for the treatment of adult and pediatric patients with recurrent \nlocally advanced or metastatic Merkel cell carcinoma. (1.14) \nRenal Cell Carcinoma (RCC) \n\u2022 in combination with axitinib, for the first-line treatment of adult \npatients with advanced RCC. (1.15) \n\u2022 in combination with lenvatinib, for the first-line treatment of \nadult patients with advanced RCC. (1.15) \n\u2022 for the adjuvant treatment of patients with RCC at \nintermediate-high or high risk of recurrence following \nReference ID: 5274826 \nThis label may not be the latest approved by FDA.  \nFor current labeling information, please visit https://www.fda.gov/drugsatfda  \nnephrectomy, or following nephrectomy and resection of \nmetastatic lesions. (1.15) \nEndometrial Carcinoma \n\u2022 in combination with lenvatinib, for the treatment of patients with \nadvanced endometrial carcinoma that is mismatch repair \nproficient (pMMR) as determined by an FDA-approved test or \nnot MSI-H, who have disease progression following prior \nsystemic therapy in any setting and are not candidates for \ncurative surgery or radiation. (1.16, 2.1) \n\u2022 as a single agent, for the treatment of patients with advanced \nendometrial carcinoma that is MSI-H or dMMR, as determined \nby an FDA-approved test, who have disease progression \nfollowing prior systemic therapy in any setting and are not \ncandidates for curative surgery or radiation. (1.16, 2.1) \nTumor Mutational Burden-High (TMB-H) Cancer \n\u2022 for the treatment of adult and pediatric patients with \nunresectable or metastatic tumor mutational burden-high \n(TMB-H) [\u226510 mutations/megabase (mut/Mb)] solid tumors, as \ndetermined by an FDA-approved test, that have progressed \nfollowing prior treatment and who have no satisfactory \nalternative treatment options.1 (1.17, 2.1) \n\u2022 Limitations of Use: The safety and effectiveness of \nKEYTRUDA in pediatric patients with TMB-H central nervous \nsystem cancers have not been established. \nCutaneous Squamous Cell Carcinoma (cSCC) \n\u2022 for the treatment of patients with recurrent or metastatic cSCC \nor locally advanced cSCC that is not curable by surgery or \nradiation. (1.18) \nTriple-Negative Breast Cancer (TNBC) \n\u2022 for the treatment of patients with high-risk early-stage TNBC in \ncombination with chemotherapy as neoadjuvant treatment, and \nthen continued as a single agent as adjuvant treatment after \nsurgery. (1.19) \n\u2022 in combination with chemotherapy, for the treatment of \npatients with locally recurrent unresectable or metastatic \nTNBC whose tumors express PD-L1 (CPS \u226510) as determined \nby an FDA approved test. (1.19, 2.1) \nAdult Classical Hodgkin Lymphoma and Adult Primary Mediastinal \nLarge B-Cell Lymphoma: Additional Dosing Regimen of 400 mg \nEvery 6 Weeks \n\u2022 for use at an additional recommended dosage of 400 mg every \n6 weeks for Classical Hodgkin Lymphoma and Primary \nMediastinal Large B-Cell Lymphoma in adults.2 (1.20, 2.2) \n1 This indication is approved under accelerated approval based on \ntumor response rate and durability of response. Continued \napproval for this indication may be contingent upon verification \nand description of clinical benefit in the confirmatory trials. \n2 This indication is approved under accelerated approval based on \npharmacokinetic data, the relationship of exposure to efficacy, \nand the relationship of exposure to safety. Continued approval for \nthis dosing may be contingent upon verification and description of \nclinical benefit in the confirmatory trials. \n-----------------------",
  "INDICATIONS AND USAGE--------------------------\nLYTGOBI is a kinase inhibitor indicated for the treatment of adult patients \nwith previously treated, unresectable, locally advanced or metastatic \nintrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 \n(FGFR2) gene fusions or other rearrangements. (1, 2.1) \nThis indication is approved under accelerated approval based on overall \nresponse rate and duration of response. Continued approval for this indication \nmay be contingent upon verification and description of clinical benefit in a \nconfirmatory trial(s). (1) \n------------------------",
  "INDICATIONS AND USAGE---------------------------\nREZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated \nfor the treatment of adult patients with relapsed or refractory acute \nmyeloid leukemia (AML) with a susceptible IDH1 mutation as detected \nby an FDA-approved test. (1) \n------------------------",
  "INDICATIONS AND USAGE _________________  \nKRAZATI is an inhibitor of the RAS GTPase family indicated for the \ntreatment of adult patients with KRAS G12C-mutated locally advanced or \nmetastatic non-small cell lung cancer (NSCLC), as determined by an FDA \napproved test, who have received at least one prior systemic therapy. (1) \nThis indication is approved under accelerated approval based on objective \nresponse rate (ORR) and duration of response (DOR). Continued approval for \nthis indication may be contingent upon verification and description of a \nclinical benefit in a confirmatory trial(s). (1) \n  _______________",
  "INDICATIONS AND USAGE----------------------------\nORSERDU is an estrogen receptor antagonist indicated for: \n\u2022 treatment of postmenopausal women or adult men, with ER-\npositive, HER2-negative, ESR1-mutated advanced or metastatic \nbreast cancer with disease progression following at least one line \nof endocrine therapy (1) \n-----------------------",
  "INDICATIONS AND USAGE---------------------------\nAKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase \n(PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with \nprednisone for the treatment of adult patients with deleterious or suspected \ndeleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate \ncancer (mCRPC). Select patients for therapy based on an FDA-approved test \nfor AKEEGA. (1, 2.1) \n------------------------",
  "INDICATIONS AND USAGE---------------------------- Evaluate clinical chemistries, including liver enzymes, creatinine, and \nJEMPERLI is a programmed death receptor-1 (PD-1)\u2013blocking antibody thyroid function, at baseline and periodically during treatment. Withhold \nindicated: or permanently discontinue JEMPERLI and administer corticosteroids \nEndometrial Cancer (EC) based on the severity of reaction. (2.3, 5.1) \n\u2022 in combination with carboplatin and paclitaxel, followed by JEMPERLI \u2022 Infusion-related reactions: Interrupt, slow the rate of infusion, or \nas a single agent for the treatment of adult patients with primary advanced permanently discontinue JEMPERLI based on severity of reaction. (2.3, \nor recurrent endometrial cancer that is mismatch repair deficient 5.2) \n(dMMR), as determined by an FDA-approved test, or microsatellite \u2022 Complications of allogeneic hematopoietic stem cell transplantation instability-high (MSI-H). (1.1, 2.1) (HSCT): Fatal and other serious complications can occur in patients who \n\u2022 as a single agent for the treatment of adult patients with dMMR recurrent receive allogeneic HSCT before or after being treated with a \nor advanced endometrial cancer, as determined by an FDA-approved test, PD-1/PD-L1\u2013blocking antibody. (5.3) \nthat has progressed on or following prior treatment with a platinum- \u2022 Embryo-fetal toxicity: Can cause fetal harm. Advise females of containing regimen in any setting and are not candidates for curative reproductive potential of the potential risk to a fetus and to use effective surgery or radiation. (1.1, 2.1) contraception. (5.4, 8.1, 8.3) Mismatch Repair Deficient Recurrent or Advanced Solid Tumors \n\u2022 as a single agent for the treatment of adult patients with dMMR recurrent ------------------------------- ADVERSE REACTIONS ------------------------------\nor advanced solid tumors, as determined by an FDA-approved test, that \u2022 Most common adverse reactions (\u226520%) with JEMPERLI in \nhave progressed on or following prior treatment and who have no combination with carboplatin and paclitaxel in patients with \nsatisfactory alternative treatment options.1 (1, 2.1) dMMR/MSI-H EC are rash, diarrhea, hypothyroidism, and hypertension. \n1This indication is approved under accelerated approval based on tumor Most common Grade 3 or 4 laboratory abnormalities (\u226510%) are \nresponse rate and durability of response. Continued approval for this decreased neutrophils, decreased hemoglobin, decreased white blood \nindication may be contingent upon verification and description of clinical cell count, decreased lymphocytes, increased glucose, decreased sodium, \nbenefit in a confirmatory trial(s). (1) and decreased platelets. (6.1) \n\u2022 Most common adverse reactions (\u226520%) with JEMPERLI as a single ------------------------",
  "INDICATIONS AND USAGE --------------------------\nTRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for \nthe treatment of adult patients with hormone receptor (HR)-positive, human \nepidermal growth factor receptor 2 (HER2)-negative, locally advanced or \nmetastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as \ndetected by an FDA-approved test following progression on at least one \nendocrine-based regimen in the metastatic setting or recurrence on or within \n12 months of completing adjuvant therapy. (1) \n----------------------",
  "INDICATIONS AND USAGE---------------------------\nTEPMETKO is a kinase inhibitor indicated for the treatment of adult patients \nwith metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-\nepithelial transition (MET) exon 14 skipping alterations. (1) \n-----------------------",
  "INDICATIONS AND USAGE---------------------------\nAUGTYRO is a kinase inhibitor indicated for the treatment of adult patients \nwith locally advanced or metastatic ROS1-positive non-small cell lung cancer \n(NSCLC). (1) \n-----------------------",
  "INDICATIONS AND USAGE--------------------------- \nICLUSIG is a kinase inhibitor indicated for the treatment of adult \npatients with: \nPhiladelphia Chromosome-Positive Acute Lymphoblastic Leukemia \n(Ph+ ALL) \n\u2022 Newly diagnosed Ph+ ALL, in combination with chemotherapy. (1) \nThis indication is approved under accelerated approval based on \nminimal residual disease (MRD)-negative complete remission \n(CR) at the end of induction. Continued approval for this \nindication may be contingent upon verification of clinical benefit in \na confirmatory trial(s). \n\u2022 As monotherapy in Ph+ ALL for whom no other kinase inhibitors \nare indicated or T315I-positive Ph+ ALL. (1) \nChronic Myeloid Leukemia (CML) \n\u2022 Chronic phase (CP) CML with resistance or intolerance to at least \ntwo prior kinase inhibitors. (1) \n\u2022 Accelerated phase (AP) or blast phase (BP) CML for whom no \nother kinase inhibitors are indicated. (1) \n\u2022 T315I-positive CML (chronic phase, accelerated phase, or blast \nphase). (1) \nLimitations of Use: ICLUSIG is not indicated and is not recommended \nfor the treatment of patients with newly diagnosed CP-CML. (5.7) \n------------------------"
]